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Background: Takotsubo cardiomyopathy (TCM) is a reversible diseas, often associated with stress. The prognosis is favorable with a low risk of 
sudden death (SCD) and the utility of a wearable cardioverter-defibrillator (WCD) in the acute phase, while the left ventricular ejection fraction (EF) 
is < 35%, is unknown. To understand this population, we reviewed the database of TCM patients who were prescribed a WCD.
methods: The WCD database included all patients who wore a WCD the United States, from August 2007 through February 2012 . The database 
contains indications, baseline demographics (age and sex), compliance, reasons for ending use, and events. TCM patients were identified by 
searching the database for ICD-9 code 429.83, or medical order notes. A physician determined whether WCD shocks to be appropriate. Mortality 
outcomes of WCD patients were determined from the Social Security Death Index (SSDI). A non-compliant patient was one who reported stopping 
WCD use prior to discontinuation of therapy by a physician.
results: One-hundred and two patients with mean age 63 ± 12 years, 11% men, had an initial EF of 27 ± 6 % at the time of WCD prescription. 
WCD was indicated as primary prevention in 93% of patients, while 7% had experienced a prior sustained VA event. The mean days of use was 44 ± 
31 days and the average follow-up period was 440 ± 374 days with a median of 288 days. WCD compliance was assessed as % days worn and % 
hours/day worn: 95% of patients wore the WCD > 90% of prescribed days and 72% of patients wore the WCD > 90% of prescribed hours. Outcomes: 
two patients (2%) experienced appropriate shocks for VA ; two patients (2%) experienced significant bradyarrhythmias needing pacing therapy; one 
patient received two inappropriate shocks; two patients died during the prescription period - one with asystole, and one while not wearing the WCD; 
five patients died after discontinuing WCD usage, two of whom had an EF ≥ 35% at the time of WCD discontinuation.
conclusions: The WCD was used with a compliance of > 90%. The device detects VAs reliably with a low risk of inappropriate shocks. TCM may be 
associated with a significant risk of death due to tachy- or brady-arrhythmias and the risk of SCD may persist even if EF increases ≥ 35%.
